Brief: Simcere Pharmaceutical Says Breakthrough Therapy Designation Granted By U.S. FDA
02/09/2024 15:42
Sept 2 (Reuters) - Simcere Pharmaceutical Group Ltd
2096.HK :
* BREAKTHROUGH THERAPY DESIGNATION OF SANBEXIN SUBLINGUAL
TABLETS
GRANTED BY U.S. FOOD AND DRUG ADMINISTRATION
Further company coverage: 2096.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660